Molecular structure of Mitotane, CAS Number: 53-19-0
Mitotane (CAS 53-19-0)
See product citations (1)
Alternate Names:
(2,4′-Dichlorodiphenyl)dichloroethane; o,p′-DDD
Application:
Mitotane is an adrenal cytotoxic agent
CAS Number:
53-19-0
Purity:
98%
Molecular Weight:
320.04
Molecular Formula:
C14H10Cl4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Mitotane, or o,p'-DDD, is a derivative of DDT (sc-238975) with antiproliferative properties. A study of the antiproliferative effects of Mitotane demonstrated particular efficacy against adrenocortical carcinoma.
Mitotane (CAS 53-19-0) References
- Mitotane treatment for adrenocortical carcinoma: an overview. | De Francia, S., et al. 2012. Minerva Endocrinol. 37: 9-23. PMID: 22382612
- Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. | Luton, JP., et al. 1990. N Engl J Med. 322: 1195-201. PMID: 2325710
- Practical treatment using mitotane for adrenocortical carcinoma. | Terzolo, M., et al. 2014. Curr Opin Endocrinol Diabetes Obes. 21: 159-65. PMID: 24732405
- Understanding mitotane mode of action. | Waszut, U., et al. 2017. J Physiol Pharmacol. 68: 13-26. PMID: 28456766
- Pharmacological profile and effects of mitotane in adrenocortical carcinoma. | Corso, CR., et al. 2021. Br J Clin Pharmacol. 87: 2698-2710. PMID: 33382119
- The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging. | Haider, MS., et al. 2021. Eur J Drug Metab Pharmacokinet. 46: 575-593. PMID: 34287806
- Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy. | Altieri, B., et al. 2022. Minerva Endocrinol (Torino). 47: 203-214. PMID: 34881855
- Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma. | Warde, KM., et al. 2022. Endocrinology. 163: PMID: 35797592
- Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline. | Poirier, J., et al. 2023. J Clin Endocrinol Metab. 108: 2336-2342. PMID: 36856782
- Cytotoxic chemotherapy in adrenal cortical carcinoma. | Haq, MM., et al. 1980. Cancer Treat Rep. 64: 909-13. PMID: 7448828
Inhibitor of:
COA1, Cortisol, CYP11A1, CYP11B, CYP11B1, DEXI, EG626305, EG667693, Fdx1, FEV, FTZ-F1, GLCCI1, Gonadotropin α, MC2-R, MRAP, NK-3R, OR8D4, Peroxin 7, SPATA32, SSTR5, StAR, StARD5, TMPRSS7, TRAP-1, TTC34, and ZP1.Activator of:
Cyclophilin C, Cyp21a1, and SerpinA6.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Mitotane, 100 mg | sc-205754 | 100 mg | $72.00 | |||
Mitotane, 1 g | sc-205754A | 1 g | $166.00 |